{site_meta && site_meta.display_name} Logo

InvestorBrandNetwork (IBN)

The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.

RSS Feed for InvestorBrandNetwork (IBN)

InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies

June 2, 2026Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how biotechnology companies are increasingly focusing on advanced drug delivery technologies to enhance the effectiveness of existing cancer therapies. The article highlights growing industry interest in nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic approaches designed to improve bioavailability, systemic exposure, tolerability and dosing consistency.


BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies

June 2, 2026Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how biotechnology companies are increasingly focusing on advanced drug delivery technologies to enhance the effectiveness of existing cancer therapies. The article highlights growing industry interest in nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic approaches designed to improve bioavailability, systemic exposure, tolerability and dosing consistency.


BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Phase 2 HARMONIC Trial Data Supporting LP-300 in EGFR-Mutant Lung Cancer

June 2, 2026Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, reported updated Phase 2 HARMONIC trial data showing that LP-300, in combination with carboplatin and pemetrexed, demonstrated a progression-free survival benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who had progressed following TKI therapy. The emerging data showed a median progression-free survival of 8.


FinTechs on Notice as Digital Fraud Ticks Upwards

June 2, 2026The rapid shift of financial services into digital spaces is creating new opportunities for cybercriminals, many of whom are increasingly relying on AI to outsmart security checks. From fabricated identities to altered documents, fraudsters are using advanced tools to bypass verification systems that many financial technology companies still struggle to secure.